NCT04036201

Brief Summary

The aim of this study is to calculate the minimum effective volume of local anesthetic for peribulbar block in patients undergoing cataract extraction surgery.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
121

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Jul 2019

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

July 22, 2019

Completed
7 days until next milestone

First Posted

Study publicly available on registry

July 29, 2019

Completed
2 days until next milestone

Study Start

First participant enrolled

July 31, 2019

Completed
2 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 10, 2019

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

October 10, 2019

Completed
Last Updated

October 22, 2019

Status Verified

October 1, 2019

Enrollment Period

2 months

First QC Date

July 22, 2019

Last Update Submit

October 18, 2019

Conditions

Keywords

Peribulbar blockminimum effective volumeaxial eye length

Outcome Measures

Primary Outcomes (1)

  • The minimum effective volume of local anesthetic of the eye in relation to the eyeball axial length.

    The minimum effective volume of local anesthetic in peribulbar block in relation to the eyeball axial length.The minimum volume which will achieve adequate sensory and motor block within 10 minutes.

    10 minutes

Study Arms (2)

Group 1(22-24 mm)

EXPERIMENTAL

Group 1 (patients with axial length between 22 and 24 mm): received a mixture of bupivacaine 0.5% (3ml) + lidocaine 2% (3ml) + hyalurindase 150 IU (1 ml) to a total volume of 7 ml.

Drug: Bupivacaine

Group 2(24.1-26 mm)

EXPERIMENTAL

Group 2 (patients with axial length between 24.1 and 26 mm): received a mixture of bupivacaine 0.5% (3ml) + lidocaine 2% (3ml) + hyaluronidase 150 IU (1 ml) to a total volume of 7 m

Drug: Bupivacaine

Interventions

peribulbar block

Also known as: hyaluronic acid
Group 1(22-24 mm)Group 2(24.1-26 mm)

Eligibility Criteria

Age40 Years - 70 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • we allocated adult patients aged 40-70 years, of both gender, American Society of Anesthesiologists (ASA) II - III, listed for elective cataract extraction using phaco emulsification technique with intraocular lens implantation surgery.

You may not qualify if:

  • Patients known to have any systemic contraindications (as severe hypertension) or allergy to the local anesthetic, those who refused local anesthesia, high myopes (axial length \> 26 mm), patients with a single eye, those with complicated vitreous hemorrhage, ocular infection, or associated glaucoma have been excluded.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Faculty of Medicine ,Ain Shams University

Cairo, Cairo Governorate, 11566, Egypt

Location

Related Publications (1)

  • El Fawal SM, Nofal WH, Sabek EAS, Abdelaal WA. Minimum effective volume of local anesthetic in peribulbar block: does it differ with the eyeball axial length? Braz J Anesthesiol. 2021 Nov-Dec;71(6):635-641. doi: 10.1016/j.bjane.2021.09.001. Epub 2021 Sep 22.

MeSH Terms

Interventions

BupivacaineHyaluronic Acid

Intervention Hierarchy (Ancestors)

AnilidesAmidesOrganic ChemicalsAniline CompoundsAminesGlycosaminoglycansPolysaccharidesCarbohydrates

Study Officials

  • WALID Nofal, MD

    Faculty of Medicine, Ain Shams University

    PRINCIPAL INVESTIGATOR
  • Sanaa el Fawal, MD

    Faculty of Medicine, Ain Shams University

    PRINCIPAL INVESTIGATOR
  • Wail Abdelaal, MD

    Faculty of Medicine, Ain Shams University

    PRINCIPAL INVESTIGATOR
  • Eman Sabek, MD

    National Centre of Radiation Research and Technology, Atomic Energy Authority

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, OUTCOMES ASSESSOR
Purpose
HEALTH SERVICES RESEARCH
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assisstant Professor of Anesthesiology

Study Record Dates

First Submitted

July 22, 2019

First Posted

July 29, 2019

Study Start

July 31, 2019

Primary Completion

October 10, 2019

Study Completion

October 10, 2019

Last Updated

October 22, 2019

Record last verified: 2019-10

Data Sharing

IPD Sharing
Will not share

Locations